A
Angela Dispenzieri
Researcher at Mayo Clinic
Publications - 1212
Citations - 72269
Angela Dispenzieri is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Multiple myeloma & Amyloidosis. The author has an hindex of 117, co-authored 1107 publications receiving 60367 citations. Previous affiliations of Angela Dispenzieri include University of Rochester & Kyungpook National University Hospital.
Papers
More filters
Journal ArticleDOI
Evidence for cytogenetic and fluorescence in situ hybridization risk stratification of newly diagnosed multiple myeloma in the era of novel therapies
Prashant Kapoor,Rafael Fonseca,S. Vincent Rajkumar,Shirshendu Sinha,Morie A. Gertz,A. Keith Stewart,P. Leif Bergsagel,Martha Q. Lacy,David D. Dingli,Rhett P. Ketterling,Francis K. Buadi,Robert A. Kyle,Thomas E. Witzig,Philip R. Greipp,Angela Dispenzieri,Shaji Kumar +15 more
TL;DR: This study validates the high-risk features defined by FISH and CG in the Mayo risk-stratification model for patients with MM predominantly treated with novel therapies based on immunomodulatory agents.
Journal ArticleDOI
Ocular Manifestations of Familial Transthyretin Amyloidosis
Margaret M. Reynolds,Kevin K. Veverka,Morie A. Gertz,Angela Dispenzieri,Steven R. Zeldenrust,Nelson Leung,Jose S. Pulido +6 more
TL;DR: In this large cohort of patients with TTR amyloidosis, female sex and decreased VA were associated with ocular amylid, and three TTR mutations, Glu89Lys, Gly47Arg, and homozygous Gly6Ser, not previously described, wereassociated with vitreous amyloids.
Journal ArticleDOI
Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)
Thierry Facon,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Cyrille Hulin,Michele Cavo,Antonella Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,James D. Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Lofti Benboubker +31 more
TL;DR: Continuous treatment with the all oral doublet Rd significantly improved the primary endpoint of PFS compared with the standard triplet, MPT, and all secondary endpoints support the clinical benefit of continuous Rd treatment.
Journal ArticleDOI
Vascular endothelial growth factor and POEMS.
TL;DR: With auto-PBSCT treatment, the symptoms of POEMS improved, and the serum VEGF levels decreased dramatically to normal or near-normal levels, by contrast, with low-dose melphalan therapy, the effects were not as large, were …
Journal ArticleDOI
Novel type of renal amyloidosis derived from apolipoprotein-CII
Samih H. Nasr,Surendra Dasari,Linda Hasadsri,Jason D. Theis,Julie A. Vrana,Morie A. Gertz,Prasuna Muppa,Michael T. Zimmermann,Karen L. Grogg,Angela Dispenzieri,Sanjeev Sethi,W. Edward Highsmith,Giampaolo Merlini,Nelson Leung,Paul J. Kurtin +14 more
TL;DR: It is proposed that this study reveals a new form of hereditary amyloidosis (AApoCII) that is derived from the Apo-CII protein and appears to manifest in the elderly and preferentially affect the kidneys.